title: [Abnormal Expression and Clinical Significance of B Lymphocyte Stimulating Factor in B Cell-derived Malignant Hematologic Diseases].
abstract: OBJECTIVE
  To explore the expression and clinical significance of B cell lymphocyte stimulating factor (BLyS) in B cell-derived malignant hematological diseases.
  
  
  METHODS
  Fifty-seven cases of newly diagnosed B cell-derived hematologic malignancies were admitted and treated in our hospital from March 2015 to 2016 July. including 17 cases of multiple myeloma(MM) (A group) and 40 cases of B cell non-Hodgkin's lymphoma(B-NHL) (B group), 30 healthy volunteers were enrolled in control group(C group). The BLyS level in peripheral blood of A,B and C groups was detected by ELISA kit; for patient with hematologic malignancies, the BLyS level was detected again after chemotherapy and was compared with level before chemotherapy.
  
  
  RESULTS
  The BLyS level in patients with B cell-derived hematologic malignancies significantly increased, as compared with healthy volanteers(P<0.05). After chemotherapy, the BLyS level in patients all significantly dicreased (P<0.05); the BLyS level in peripheral blood of DLBCL and FL patients was significantly higher than that in patients with B-NHL of other types(P<0.05); the BLyS level in peripheral blood of patients at III-IV stage was significantly higher than that in patients at I-II stage.
  
  
  CONCLUSIONS
  The BLyS expression in B cell derived hematologic malignancies significantly increases, moreover the its expression level in B-NHL patients at different stages and histologic types is different, suggesting that detection of BLyS expression level in patients in vivo possesses a certain guiding role for diagnosis, staging and treatment of B cell-derived hematologic malignancies.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, School of Pharmacy, Xinxiang Medical University, Xinxiang 453000, Henan Province, China. E-mail: 925214597@qq.com.
authors.forename: Xiao-Lin
authors.initials: XL
authors.lastname: Han
authors.affiliation: Department of Pharmacology, School of Pharmacy, Xinxiang Medical University, Xinxiang 453000, Henan Province, China.
authors.forename: Xiao-Yi
authors.initials: XY
authors.lastname: Zhang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, School of Pharmacy, Xinxiang Medical University, Xinxiang 453000, Henan Province, China.
authors.forename: Jing-Dong
authors.initials: JD
authors.lastname: Li
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, School of Pharmacy, Xinxiang Medical University, Xinxiang 453000, Henan Province, China.
authors.forename: Wan-Ling
authors.initials: WL
authors.lastname: Wang
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Xinxiang Medical University, School of Pharmacy, Xinxiang Medical University, Xinxiang 453000, Henan Province, China.
authors.forename: Cui
authors.initials: C
authors.lastname: Yang
mesh_terms: D053264:B-Cell Activating Factor; D001402:B-Lymphocytes; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology* / Q000378:metabolism
chemical_list: D053264:B-Cell Activating Factor